AstraZeneca PLC’s new antibacterial, Zavicefta (ceftazidime plus avibactam), has been recommended for approval in the EU by the top advisory panel, the Committee for Medicinal Products for Human Use (CHMP), for use in the treatment of patients infected with multi-drug resistant bacteria, so-called “superbugs”, as well as several other severe bacterial infections.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?